Sanofi Acquires US Vaccine Biotech Firm

Jul 11, 2017
By Pharmaceutical Executive Editors

Sanofi has announced it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, CT. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones.  

Protein Sciences received FDA approval in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV), which is the only recombinant protein-based influenza vaccine approved by the Agency. 

“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi Executive Vice President and Head of Sanofi Pasteur, Sanofi’s vaccines division.

The acquisition is expected to close in the third quarter of 2017.

native1_300x100
lorem ipsum